Indications for: VARIVAX

Varicella (chickenpox) vaccination.

Adult Dosage:

Give by SC or IM inj. ≥13yrs: 1 dose of 0.5mL at elected date and a 2nd dose of 0.5mL at least 4 weeks later.

Children Dosage:

<12mos: not established. Give by SC or IM inj. 12mos–12yrs: administer 1st dose of 0.5mL at 12 to 15 months of age but may give anytime through 12yrs of age, then give 2nd dose at 4–6yrs of age. 

VARIVAX Contraindications:

Hypersensitivity to gelatin or neomycin. Immunodeficient or immunosuppressed. Active febrile illness with fever >101.3⁰F (>38.5⁰C). Active untreated tuberculosis. During pregnancy or individuals who are planning on becoming pregnant in the next 3 months. 

VARIVAX Warnings/Precautions:

Have epinephrine inj (1:1000) available. Defer vaccination if family history of congenital or hereditary immunodeficiency until immunocompetent. Avoid contact with susceptible high-risk individuals for up to 6 weeks after vaccination. HIV-infected: refer to ACIP recommendations. Nursing mothers.

VARIVAX Classification:


VARIVAX Interactions:

Avoid salicylates in patients (12 months through 17 years of age) for 6 weeks after vaccination. Concomitant administration with immune globulins and other blood products may interfere with the expected immune response; refer to ACIP recommendations. May interfere with tuberculin skin test. Separate by at least 1 month between a dose of a live attenuated measles virus-containing vaccine and Varivax. In children through 12yrs, separate by at least 3 months between 2 doses of a live attenuated varicella virus-containing vaccine and Varivax.

Adverse Reactions:

Fever, inj site reactions, rash; others.

Generic Drug Availability:


How Supplied:

Single-dose vials—10 (w. diluent)